Scientific article

Polyarthrite rhumatoïde,méthotrexate et fibrose pulmonaire : quelles évidences ?

Published inRevue médicale suisse, vol. 6, no. 240, p. 547-554
Publication date2010

Pulmonary fibrosis is an extraarticular manifestation of rheumatoid arthritis (RA), which appears between 20 to 40% of cases. MTX is an ordinary treatment used for patients with RA. It has been suggested in some studies that a link between the use of MTX and the appearance of pulmonary fibrosis exists. Furthermore, the chronic use of MTX has been associated with the development of hepatic cirrhosis. Adenosine, a key molecule in the anti-inflammatory action of MTX seems to have a pro-fibrotic effect in some experimental models, thereby suggesting a mechanism through which MTX could lead to a fibrotic process. However, in spite of these experimental models, clinical studies have not permitted to confirm the pathogenic role of MTX in pulmonary fibrosis.

  • Adenosine/adverse effects/metabolism
  • Animals
  • Arthritis, Rheumatoid/complications/drug therapy/pathology
  • Humans
  • Liver Cirrhosis/chemically induced
  • Methotrexate/adverse effects/therapeutic use
  • Pulmonary Fibrosis/chemically induced/etiology
  • Smoking/adverse effects
Citation (ISO format)
SCHALLER, Dorian, NENDAZ, Mathieu, GABAY, Cem. Polyarthrite rhumatoïde,méthotrexate et fibrose pulmonaire : quelles évidences ? In: Revue médicale suisse, 2010, vol. 6, n° 240, p. 547–554.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation11/30/2012 9:55:00 AM
First validation11/30/2012 9:55:00 AM
Update time03/14/2023 5:46:00 PM
Status update03/14/2023 5:46:00 PM
Last indexation01/16/2024 12:34:35 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack